Argos Therapeutics Inc (NASDAQ:ARGS) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a report released on Monday.

According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “

Other research analysts have also recently issued reports about the company. FBR & Co reissued a “buy” rating and set a $13.00 price objective on shares of Argos Therapeutics in a report on Tuesday, January 17th. Stifel Nicolaus cut Argos Therapeutics from a “buy” rating to a “hold” rating and set a $1.40 price objective for the company. in a report on Wednesday, February 22nd. Needham & Company LLC cut Argos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 22nd. Finally, JMP Securities cut Argos Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 22nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. Argos Therapeutics has an average rating of “Hold” and a consensus target price of $4.78.

Shares of Argos Therapeutics (NASDAQ:ARGS) traded down 0.09% during mid-day trading on Monday, hitting $0.43. 375,418 shares of the company’s stock were exchanged. The company’s market capitalization is $17.78 million. Argos Therapeutics has a 52 week low of $0.31 and a 52 week high of $9.22. The firm has a 50 day moving average price of $0.44 and a 200-day moving average price of $3.10.

ILLEGAL ACTIVITY NOTICE: “Argos Therapeutics Inc (ARGS) Rating Lowered to Sell at Zacks Investment Research” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/05/15/argos-therapeutics-inc-args-rating-lowered-to-sell-at-zacks-investment-research.html.

An institutional investor recently raised its position in Argos Therapeutics stock. State Street Corp raised its position in shares of Argos Therapeutics Inc (NASDAQ:ARGS) by 11.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 177,494 shares of the biopharmaceutical company’s stock after buying an additional 18,625 shares during the period. State Street Corp owned 0.43% of Argos Therapeutics worth $870,000 at the end of the most recent reporting period. Institutional investors own 15.25% of the company’s stock.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

5 Day Chart for NASDAQ:ARGS

Get a free copy of the Zacks research report on Argos Therapeutics (ARGS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Argos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.